Cellectar Biosciences Management
Management criteria checks 2/4
Cellectar Biosciences' CEO is Jim Caruso, appointed in Jun 2015, has a tenure of 9.42 years. total yearly compensation is $1.97M, comprised of 30.5% salary and 69.5% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $79.24K. The average tenure of the management team and the board of directors is 2.8 years and 8.5 years respectively.
Key information
Jim Caruso
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 30.5% |
| CEO tenure | 9.4yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.8yrs |
| Board average tenure | 8.5yrs |
Recent management updates
Recent updates
We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully
Aug 08
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss
Feb 12Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation
Aug 23Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19
Aug 05Cellectar announces reverse stock split
Jul 21We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate
May 10Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?
Jan 20Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?
Oct 05Cellectar shares fall after mid-stage CLR 131 trial data fails to impress
Jun 04We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely
May 20Cellectar Biosciences EPS beats by $0.03
May 10Cellectar gets notification of formal grant from Australian and Mexican patent authorities
Apr 27Cellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancer
Jan 12Cellectar Bio readies stock offering
Dec 23We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate
Nov 30
Cellectar Biosciences EPS beats by $0.05
Nov 09Cellectar Bio's lead asset shows encouraging action in early-stage study of pediatric tumors
Nov 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$50m |
| Jun 30 2024 | n/a | n/a | -US$53m |
| Mar 31 2024 | n/a | n/a | -US$62m |
| Dec 31 2023 | US$2m | US$600k | -US$43m |
| Sep 30 2023 | n/a | n/a | -US$42m |
| Jun 30 2023 | n/a | n/a | -US$36m |
| Mar 31 2023 | n/a | n/a | -US$33m |
| Dec 31 2022 | US$1m | US$569k | -US$32m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$25m |
| Mar 31 2022 | n/a | n/a | -US$24m |
| Dec 31 2021 | US$2m | US$523k | -US$24m |
| Sep 30 2021 | n/a | n/a | -US$22m |
| Jun 30 2021 | n/a | n/a | -US$20m |
| Mar 31 2021 | n/a | n/a | -US$17m |
| Dec 31 2020 | US$1m | US$475k | -US$15m |
| Sep 30 2020 | n/a | n/a | -US$15m |
| Jun 30 2020 | n/a | n/a | -US$15m |
| Mar 31 2020 | n/a | n/a | -US$14m |
| Dec 31 2019 | US$934k | US$451k | -US$14m |
| Sep 30 2019 | n/a | n/a | -US$15m |
| Jun 30 2019 | n/a | n/a | -US$16m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | US$770k | US$425k | -US$15m |
| Sep 30 2018 | n/a | n/a | -US$17m |
| Jun 30 2018 | n/a | n/a | -US$15m |
| Mar 31 2018 | n/a | n/a | -US$16m |
| Dec 31 2017 | US$994k | US$410k | -US$15m |
Compensation vs Market: Jim's total compensation ($USD1.97M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.
CEO
Jim Caruso (65 yo)
9.4yrs
Tenure
US$1,965,140
Compensation
Mr. James V. Caruso, also known as Jim, is Member of Advisory Board & Director of Hip Innovation Technology, LLC. Mr. Caruso has been the Chief Executive Officer and President of Cellectar Biosciences, Inc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9.4yrs | US$1.97m | 0.14% $ 79.2k | |
| VP, CFO & Secretary | 2.8yrs | US$1.11m | 0.12% $ 68.6k | |
| Chief Operating Officer | 2.8yrs | US$1.36m | 0.15% $ 85.6k | |
| Chief Commercial Officer | 2yrs | no data | 0.11% $ 63.8k | |
| Senior Vice President of Medical | 1.8yrs | no data | 0.15% $ 88.6k |
2.8yrs
Average Tenure
52yo
Average Age
Experienced Management: CLRB's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9.4yrs | US$1.97m | 0.14% $ 79.2k | |
| Independent Director | 16.8yrs | US$93.25k | 0.017% $ 10.1k | |
| Independent Director | 7.6yrs | US$93.25k | 0.0054% $ 3.1k | |
| Independent Director | 9.4yrs | US$93.25k | 0% $ 0 | |
| Independent Chairman of the Board | 7.6yrs | US$109.88k | 0.0070% $ 4.0k | |
| Independent Director | 3.4yrs | US$48.25k | 0% $ 0 |
8.5yrs
Average Tenure
62.5yo
Average Age
Experienced Board: CLRB's board of directors are considered experienced (8.5 years average tenure).